Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study
Authors' conclusion
Significant BMD increases were observed in the LS for all groups, in the TH for the ROMO and DMAb groups, and in the FN for the ROMO group. ROMO showed the most substantial BMD improvements following BP therapy.
Study context
- Population
- Postmenopausal osteoporosis patients who switched from bisphosphonates (BP) due to treatment inefficacy (mean age 73.8 years; prior BP 37.1 months; T-scores lumbar spine (LS) −2.8, total hip (TH) −2.5, femoral neck (FN) −2.7)45 per group after matching
- Participants
- 389 patients
- Comparison
- Switch from BP to romosozumab (ROMO) vs denosumab (DMAb) vs TPTD
- ROMOn = 45
- DMAbn = 45
- TPTDn = 45
- Outcome
- BMD increase, lumbar spine
- Follow-up
- 12 months
Methodological detailsmulticenter, propensity score matching
- Multicenter
- Propensity score matching
Main finding
As reported in the abstract
ROMO vs DMAb: P < 0.001 · ROMO vs TPTD: P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | ROMO | TPTD | P value |
|---|---|---|---|
| BMD increase, total hip · 12 monthsROMO vs TPTD | 3.3% | 0.8% | P < 0.01 |
| BMD increase, femoral neck · 12 months | 2.0% | — not stated in the abstract | P < 0.01 from baseline |
— not stated in the abstract
Bone mineral density (BMD) increase, femoral neck · 12 months
- Only the ROMO group showed a significant BMD increase in the FN
Bone turnover markers
- ROMO: decreased bone resorption and increased bone formation markers
- TPTD: highest increases in both markers
- DMAb: suppressed both markers
Original publication
Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study. Osteoporos Int. Published 16 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →